Research overview

​​At the Finsen Center our research is mainly focused on cancer, diseases of the blood and immune system, infectious diseases and various aspects of inflammation.​​​

​Disease awareness equals optimized treatment 

Understanding the nature of underlying disease mechanisms is one of our high-priority goals. Solving these riddles enables us to develop specific treatment strategies and novel methods for evaluating treatment responses, eventually leading to optimized treatment experiences for each individual patient.
Research on disease mechanisms contributes e.g. to fundamental insights into how cancer develops, and paves the way for future treatment possibilities. Furthermore, deciphering the etiology of autoimmune rheumatic diseases hopefully manifests into highly competent treatments, while avoiding inappropriate and potentially dangerous immune suppression.

Development and trial of novel therapies 

The systematic testing of different types of chemotherapies is essential in order to offer the most efficient combination of therapies with currently available medicaments.

Molecular biological profiling of certain malignancies allows us in cooperation with international partners to present treatment options that would otherwise be inaccessible. Our research on radiotherapy contributes to the invention of unique techniques and more accurate treatments with less adverse effects and late complications.
Chemotherapy, radiotherapy, and other immunosuppressant treatments are associated with increased incidence of infections. Consequently, we also conduct research on developing systems for individual risk-based therapy, with the potential to significantly reduce the problem.​

Inflammation research

Inflammation plays a significant role in cancer, diseases of the blood, rheumatism, infectious diseases, and a wide variety of lifestyle problems, including cardiovascular diseases and obesity. At the Finsen Center, our inflammatory research is in touch with both basic scientific questions and general health beneficial matters.


Responsible editor